Breaking News

Tweet TWEET

Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempra's Solithromycin (CEM-101) in a

Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes
       Studies on Cempra's Solithromycin (CEM-101) in a Cystic Fibrosis
                           Anti-inflammatory Model

PR Newswire

CHAPEL HILL, N.C., Feb. 12, 2013

CHAPEL HILL, N.C., Feb. 12, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP),
a clinical-stage pharmaceutical company focused on developing differentiated
antibiotics to meet critical medical needs in the treatment of bacterial
infectious diseases, today announced that the National Institute of Allergy
and Infectious Diseases (NIAID) awarded a grant to Richard C. Boucher, M.D.,
Kenan Professor of Medicine and director of the Cystic Fibrosis and Pulmonary
Research and Treatment Center at the University of North Carolina School of
Medicine, to investigate the anti-inflammatory activity of solithromycin and
its effect on mucin secretion in models for cystic fibrosis (CF).

Dr. Boucher's laboratory has studied the role of mucin secretion as well as
sodium transport by respiratory epithelium. His laboratory has also
investigated the anti-inflammatory activity of and inhibition of mucin
production by azithromycin, a first-generation macrolide antibiotic.
Solithromycin has demonstrated greater potency than azithromycin and other
antibiotics against respiratory pathogens as well as stronger
anti-inflammatory properties in vitro and in animal models. Dr. Boucher's
grant, entitled "Novel Therapies for Muco-Obstructive Lung Diseases," will
include tests of solithromycin for its effect on mucus production and for its
anti-inflammatory effects in models for CF.

"Treatment of cystic fibrosis patients is complicated by the secretion of
excessive mucin, which can trap bacteria, as well as promote airway
inflammation, said Dr. Boucher. "Our research is directed toward identifying
compounds that can inhibit mucin formation, reduce inflammation and restore
normal airways physiology. Macrolides, such as azithromycin, have been used
to manage these processes in CF patients in the past. Solithromycin is one of
the promising new agents in development, because of its potent
anti-inflammatory and anti-mucin activity, that could become an important
option for physicians managing CF patients."

Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra
said, "Solithromycin is emerging as a truly differentiated antibiotic that may
become an important option for physicians to treat serious infections such as
community-acquired bacterial pneumonia (CABP) or gonococcal infections.
Solithromycin has demonstrated a broad activity spectrum, including against
macrolide-resistant strains, in in vitro and in vivo models. In a Phase 2
trial of patients with gonorrhea, all patients were cured with a single dose
of solithromycin. We have recently initiated a Phase 3 trial of oral
solithromycin in CABP patients, which could result in the only macrolide being
available as oral monotherapy to treat the disease. An intravenous (IV)
formulation is also in development and we plan to start an IV-to-oral trial in
CABP in the second half of 2013. The two dosing options would enable patients
to step down from IV to oral therapy and presumably leave the hospital sooner
while staying on the same antibiotic. Dr. Boucher's research highlights
another property of the compound, its anti-inflammatory and anti-mucin
production activity. We look forward to seeing the results of his work."

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are in advanced clinical development; solithromycin in Phase 3 for
CABP and CEM-102 for prosthetic joint infections. Both seek to address the
need for new treatments targeting drug-resistant bacterial infections in the
hospital and in the community. The company also intends to use its series of
proprietary lead compounds from its novel macrolide library for uses such as
the treatment of chronic inflammatory diseases, endocrine diseases and gastric
motility disorders. Additional information about Cempra can be found at
www.cempra.com.

Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: the results
of studies of our product candidates conducted by others; the results, timing,
costs and regulatory review of our studies and clinical trials; our need to
obtain additional funding and our ability to obtain future funding on
acceptable terms; our anticipated capital expenditures and our estimates
regarding our capital requirements; our ability to obtain FDA approval of our
product candidates; our dependence on the success of solithromycin and Taksta;
and innovation by our competitors. The reader is referred to the documents
that we file from time to time with the Securities and Exchange Commission.



Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com

SOURCE Cempra, Inc.

Website: http://www.cempra.com